Relieving platelet inhibition using a novel bispecific antibody: a novel approach for circumventing the platelet storage lesion
Journal of Thrombosis and Haemostasis · 2026
DOI: 10.1016/j.jtha.2025.08.018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026. Verfasst von Alyssa J Moroi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Blood Research Institute, Versiti, Milwaukee, Wisconsin, USA. Hauptthemen laut MEDLINE: Blood Platelets, Antibodies, Bispecific, Platelet Endothelial Cell Adhesion Molecule-1, Blood Preservation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, National Institutes of Health, Conseil Régional Provence-Alpes-Côte d'Azur.
Abstract (Originalsprache)
BACKGROUND: Human platelets undergo structural and functional deterioration during extracorporeal storage at either room or cold temperature, impairing their reactivity and diminishing their hemostatic effectiveness following transfusion. PECAM-1 is an inhibitory receptor on platelets that exerts its inhibitory effects via phosphorylation of tyrosine residues that lie within its cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). OBJECTIVES: The purpose of this investigation was to attempt to restore platelet reactivity by impairing the inhibitory activity of PECAM-1. METHODS: To counteract PECAM-1-mediated inhibition, we developed a novel bispecific tandem single-chain variable fragment that ligates the protein tyrosine phosphatase, CD148, with PECAM-1, promoting dephosphorylation of PECAM-1 ITIMs. We then analyzed the ability of this engineered tandem single-chain variable fragment (taFv 179) to improve adhesion and aggregation responses in vitro and under conditions of flow. RESULTS: Addition of taFv 179 enhanced secretion, aggregation, and activation responses of both freshly isolated and stored platelets, particularly in response to weak agonists. taFv 179 also improved thrombus formation on collagen-coated surfaces under conditions of arterial flow. CONCLUSION: These findings demonstrate that enforced approximation of a phosphatase next to PECAM-1 ITIM tyrosine receptors is a novel strategy for enhancing the functionality of stored platelets, with potential implications for improving the effectiveness of platelet transfusion therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Blood Research Institute, Versiti, Milwaukee, Wisconsin, USA.
- Blood Research Institute, Versiti, Milwaukee, Wisconsin, USA; Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA; Department of Cell Biology, Neurobiology, and Anatomy, Medi…
Förderung
- NHLBI NIH HHS
- National Institutes of Health
- Conseil Régional Provence-Alpes-Côte d'Azur
- National Heart Lung and Blood Institute
Zitieren
APA
Moroi, A. J., Paddock, C., & Newman, P. J. (2026). Relieving platelet inhibition using a novel bispecific antibody: a novel approach for circumventing the platelet storage lesion. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2025.08.018
Vancouver
Moroi AJ, Paddock C, Newman PJ. Relieving platelet inhibition using a novel bispecific antibody: a novel approach for circumventing the platelet storage lesion. Journal of Thrombosis and Haemostasis. 2026. doi:10.1016/j.jtha.2025.08.018
BibTeX
@article{Moroi2026,
author = {Moroi, Alyssa J and Paddock, Cathy and Newman, Peter J},
title = {Relieving platelet inhibition using a novel bispecific antibody: a novel approach for circumventing the platelet storage lesion},
journal = {Journal of Thrombosis and Haemostasis},
year = {2026},
doi = {10.1016/j.jtha.2025.08.018}
}
EUVIMED